<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055414</url>
  </required_header>
  <id_info>
    <org_study_id>KUP-UI030-231</org_study_id>
    <nct_id>NCT05055414</nct_id>
  </id_info>
  <brief_title>Arformoterol/Budesonide for COVID-19</brief_title>
  <acronym>ABC</acronym>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2 Study to Evaluate the Efficacy and Safety of UI030 in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea United Pharm. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea United Pharm. Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase 2 study&#xD;
      to evaluate the efficacy and safety of UI030 in COVID-19 patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with moderate and severe COVID-19 were randomly assigned (1:1) to receive either&#xD;
      UI030 (Budesonide/Arformoterol dry powder inhaler, 2 inhalations b.i.d) or placebo for 2&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Clinical Improvement on World Health Organization (WHO) Ordinal Scale</measure>
    <time_frame>28 days</time_frame>
    <description>The median time to reach the clinical improvement on the WHO Ordinal 9 Scale for Clinical Improvement [0-8]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>World Health Organization (WHO) Ordinal Scale for Clinical Improvement</measure>
    <time_frame>28 days</time_frame>
    <description>Improvement rate of patients with WHO Clinical Ordinal 9 Scale [0-8]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization (WHO) Ordinal Scale change</measure>
    <time_frame>28 days</time_frame>
    <description>Change from baseline in WHO Ordinal 9 Scale [0-8]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of patients with clinical cure and improvement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>UI030</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UI030</intervention_name>
    <description>Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>UI030</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult, aged 19 years or above&#xD;
&#xD;
          -  New onset of symptoms suggestive of COVID-19 (fever, cough, soar throat, etc) or&#xD;
             diagnosed with COVID-19 within 7 days of participant being seen at visit 1&#xD;
&#xD;
          -  In the Investigator's opinion, is able and willing to comply with all trial&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A condition requiring invasive oxygen support;&#xD;
&#xD;
          -  History of hypersensitivity to budesonide and arformoterol&#xD;
&#xD;
          -  Pregnancy, Breast-feeding&#xD;
&#xD;
          -  Participation in other clinical studies within 4 weeks prior to enrollment in this&#xD;
             study.&#xD;
&#xD;
          -  Refusal of the patient to continue participating in the study/withdrawal of informed&#xD;
             consent by the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

